Truqap® Tablets for HR+ HER2- Breast Cancer

Truqap is capivasertib, an oral AKT inhibitor used with fulvestrant for certain HR-positive, HER2-negative breast cancers. This page explains how the tablets are used, safety basics, and how to order with US delivery from Canada, including options without insurance. Use it to prepare for a conversation with your prescriber.

What Truqap Is and How It Works

Truqap® contains capivasertib, a targeted therapy that blocks AKT, a key signaling protein within the PI3K/AKT pathway. Inhibition of this pathway may slow tumor cell growth and survival in endocrine-resistant disease. The medicine is taken by mouth and is used together with fulvestrant according to approved labeling.

YouDrugstore is a licensed Canadian pharmacy in Manitoba. Pharmacists review prescriptions before dispensing.

Truqap tablets work by selectively inhibiting AKT1/2/3. This action can help restore sensitivity to endocrine therapy in hormone receptor–positive, HER2-negative advanced breast cancer. Clinical use follows a cyclical oral schedule alongside fulvestrant injections prescribed by a clinician.

See our condition hub for background and support resources on Breast Cancer.

Who It’s For

This treatment is indicated for adults with HR-positive, HER2-negative locally advanced or metastatic breast cancer who have received prior endocrine therapy. It is used in combination with fulvestrant. A prescriber may confirm tumor alterations such as PIK3CA, AKT1, or PTEN, consistent with the approved use.

People with known hypersensitivity to capivasertib or its components should avoid it. Discuss pregnancy, breastfeeding, moderate to severe liver issues, poorly controlled diabetes, or a history of severe rash with a healthcare professional before starting. Lab monitoring is typically recommended during therapy.

Dosage and Usage

The schedule includes oral dosing on treatment days together with fulvestrant given per the injection label. Your prescriber determines the exact plan, including start date, on/off cycle, and any changes if side effects occur. Regimens may use Truqap 200 mg tablets as part of the total daily dose.

Take doses at roughly the same times on scheduled days. Swallow tablets whole with water. Do not crush, chew, or split. If vomiting occurs after a dose, do not repeat the dose; resume with the next scheduled time. Follow all instructions provided by your care team and the package insert.

Foods like grapefruit or Seville oranges, and drugs that strongly affect CYP3A, can change exposure. Check interactions below and review all medicines, supplements, and herbals with your clinician before starting the regimen.

Strengths and Forms

This therapy is supplied as oral film-coated tablets. Available strengths commonly include 50 mg, 100 mg, and 200 mg. Pack sizes and tablet colors may vary by manufacturer and country. Availability can change; some strengths may be limited at times.

Many patients are dispensed Capivasertib 100 mg tablets as part of a combination of strengths to achieve the prescribed dose. Final selection depends on the regimen your prescriber sets. Not all strengths may be stocked at all times.

Missed Dose and Timing

If a dose is missed, the general label guidance is to take it as soon as remembered unless it is close to the next scheduled dose. If the next dose is near, skip the missed dose and continue with the regular schedule. Do not double up to make up for a missed dose. If multiple doses are missed, contact your healthcare professional for advice.

Keep a dosing calendar or reminder to track on/off days if your plan uses cyclical dosing. Consistency supports adherence and helps your care team interpret lab results.

Storage and Travel Basics

Store tablets in the original container with the lid closed. Keep them dry and away from excessive heat and direct light. Store out of reach of children and pets. Do not use tablets past the printed expiration date.

For travel, keep the prescription label attached and carry the medicine in your hand luggage. Bring a copy of the prescription and a medication list in case security asks for documentation. If crossing borders, allow extra time for screening and keep dosing schedules in mind as time zones change.

Pen Handling and Sharps Disposal

No pens or needles are included for this medicine. Sharps disposal is not required for the tablets. Fulvestrant injections are handled separately by your clinic or as directed by your prescriber.

Benefits

This medicine is an oral targeted therapy that can work with endocrine treatment in HR-positive, HER2-negative advanced disease. It may help delay progression by addressing a known resistance pathway. The oral route avoids infusion visits, and the cyclical schedule allows off days to support tolerability. Many people appreciate the ability to take treatment at home while staying engaged with their care team.

As Capivasertib tablets are used in combination with fulvestrant, teams can tailor supportive care for rash, diarrhea, or blood sugar changes if they arise. Your clinic will advise on symptom tracking and when to call.

Side Effects and Safety

• Diarrhea or loose stools
• Skin rash or redness
• Nausea, vomiting, or decreased appetite
• Fatigue or weakness
• Mouth sores
• Headache

Serious effects can include severe skin reactions, high blood sugar, infections, or changes in certain lab tests. Dizziness or dehydration may occur if diarrhea is not managed. Call your clinician urgently for signs of severe rash, persistent high fevers, significant hyperglycemia symptoms, or other concerning reactions. Hypoglycemia can occur when used with specific diabetes medicines; blood sugar can also rise, so monitoring is common.

Drug Interactions and Cautions

Capivasertib is affected by CYP3A. Strong CYP3A inhibitors (for example, ketoconazole, clarithromycin) may raise levels; strong inducers (such as rifampin, carbamazepine, St. John’s wort) may lower exposure. Avoid grapefruit or Seville orange products. Review all prescriptions, OTC medicines, and supplements with your pharmacist or prescriber. Alcohol may worsen dehydration from diarrhea.

Use effective contraception during treatment and for the label-specified period after the last dose. Breastfeeding is not recommended during treatment and for a period afterward, per the official prescribing information.

What to Expect Over Time

Most patients follow cyclical dosing, with periodic clinic visits for exams and labs. Your team may check skin, glucose, and other labs and adjust supportive care if needed. Many side effects start early and can improve with dose pauses or standard measures recommended by your prescriber. Staying consistent with dosing days and reporting symptoms quickly helps keep treatment on track.

Educational articles about endocrine therapy partners may help you prepare for discussions, such as our overview of Exemestane 25 Mg Tablet and the Exemestane Side Effects Guide.

Compare With Alternatives

Other approved options may be considered depending on tumor subtype, prior therapies, and tolerability:

• Verzenio – a CDK4/6 inhibitor used with endocrine therapy for HR-positive, HER2-negative metastatic disease.
• Tukysa – a HER2-directed kinase inhibitor for select HER2-positive settings; not for HER2-negative disease.

Your oncology team will choose based on biomarker status, prior treatments, and overall goals.

Pricing and Access

Canadian pharmacy pricing can help lower costs compared with typical US cash-pay rates. If paying out of pocket, searching for Truqap without insurance options may help you understand expected expenses before treatment starts. YouDrugstore provides current availability and transparent listings so your clinic can plan refills.

For budget planning, ask our team about total course estimates and billing options. We publish clear information to help compare the Capivasertib cash price with other sources. Orders Cancer ship discreetly with tracking. We also support orders that Ships from Canada to US for your convenience. Checkout is protected with encrypted payment processing.

Looking for seasonal deals? See our latest offers on the Promotions page.

Availability and Substitutions

Supply can vary by strength. If a strength is temporarily unavailable, a prescriber may adjust the combination of tablet strengths or recommend an alternative therapy. Pharmacy staff will contact your clinic for any required changes. We do not provide clinical substitution without prescriber approval.

Patient Suitability and Cost-Saving Tips

Good candidates typically have HR-positive, HER2-negative advanced disease where an AKT pathway–directed combination is appropriate under current labeling. Those with active, uncontrolled infections or significant uncontrolled diabetes may need stabilization first. People with a history of severe hypersensitivity reactions to components should not take this medicine.

To manage costs, consider multi-month dispensing when the regimen is stable. Scheduling refills ahead of cycle changes reduces last-minute issues. Ask your prescriber about support programs, and provide complete insurance details, if any, to explore coverage pathways. Refill reminders and a simple dosing calendar can reduce missed doses and prevent rush orders.

Questions to Ask Your Clinician

• Is my tumor eligible for this AKT inhibitor based on biomarkers?
• How will fulvestrant be scheduled with my oral doses?
• What symptoms should prompt a call between visits?
• Which foods or medicines should I avoid during treatment?
• How often will blood sugar and labs be checked?
• If side effects occur, what are the usual management steps?

Authoritative Sources

Manufacturer Prescribing Information (AstraZeneca)

FDA DailyMed

Health Canada Drug Product Database

Ready to proceed? Buy Capivasertib online at YouDrugstore with express service and US shipping from Canada. This page is informational and does not replace advice from your healthcare professional; prescription required and verified.